Blog

A blog about children’s cancer survivors, fighters and supporters,
and the cancer research that accelerates the search for cures.

Home » Blog

Honoring Luke’s Legacy: Join Us This Childhood Cancer Awareness Month to Support Life-Saving Research

For most families, childhood cancer is unfathomable. But for families like Luke Getchell’s, childhood cancer is their heartbreaking, stomach-turning reality. In July of 2018, 13-year-old Luke was diagnosed with acute myeloid leukemia (AML) with a common genetic alteration, FLT3-ITD. That

Honoring Luke’s Legacy: Join Us This Childhood Cancer Awareness Month to Support Life-Saving Research Read More »

Luke - Childhood Cancer

New Pediatric Cancer Clinical Trial at Washington University aims to Find Alternative to Standard Therapies 

Today, we’re announcing $2M in funding for a new pediatric brain cancer clinical trial. Dr. Mohamed Abdelbaki’s team is testing a new type of cancer immunotherapy in children with recurrent brain tumors, with funding from a CureSearch Catapult Award.  August

New Pediatric Cancer Clinical Trial at Washington University aims to Find Alternative to Standard Therapies  Read More »

Mohamed S. Abdelbaki, MD

CureSearch and UK-based LifeArc to Co-fund Nearly $1.5M in High-grade Glioma Research

We’re partnering internationally to create far-reaching impact for kids with cancer We’re excited to share news of our recent partnership with LifeArc, a highly-regarded UK-based medical research charity. LifeArc will co-fund Dr. Gregory Friedman’s CureSearch Acceleration Initiative (AI) project aimed

CureSearch and UK-based LifeArc to Co-fund Nearly $1.5M in High-grade Glioma Research Read More »

Dr. Gregory Friedman blog

FDA Grants Approval of New Pediatric Glioma Drug to Day One, a Biopharma Co-founded by CureSearch Board Member Dr. Samuel Blackman

Pediatric low-grade glioma (pLGG) is the most common form of pediatric brain cancer. Day One’s OJEMDA™ is the first targeted treatment for pLGG tumors with BRAF fusions and mutations. Last week, on April 23, 2024, Day One Biopharmaceuticals was granted Accelerated

FDA Grants Approval of New Pediatric Glioma Drug to Day One, a Biopharma Co-founded by CureSearch Board Member Dr. Samuel Blackman Read More »

High-risk neuroblastoma in children has a grim outlook. Dr. Jonus is fighting to change that.

Neuroblastoma is the most common extracranial solid tumor of childhood arising within the developing nervous system. Approximately half of neuroblastoma patients are diagnosed with high-risk disease, which is especially aggressive with a 50% survival rate. If a child’s high-risk neuroblastoma

High-risk neuroblastoma in children has a grim outlook. Dr. Jonus is fighting to change that. Read More »

Dr. Hunter Jonus

Pin It on Pinterest

Scroll to Top